carprofen has been researched along with Osteoarthritis in 41 studies
carprofen: RN given refers to cpd without isomeric designation
carprofen : Propanoic acid in which one of the methylene hydrogens is substituted by a 6-chloro-9H-carbazol-2-yl group. A non-steroidal anti-inflammatory drug, it is no longer used in human medicine but is still used for treatment of arthritis in elderly dogs.
Osteoarthritis: A progressive, degenerative joint disease, the most common form of arthritis, especially in older persons. The disease is thought to result not from the aging process but from biochemical changes and biomechanical stresses affecting articular cartilage. In the foreign literature it is often called osteoarthrosis deformans.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A multi-site, masked, randomised parallel group study employing a double dummy treatment design was performed in canine veterinary patients to determine the comparative efficacy and safety of mavacoxib and carprofen in the treatment of pain and inflammation associated with osteoarthritis for a period of 134 days." | 9.20 | Comparative efficacy and safety of mavacoxib and carprofen in the treatment of canine osteoarthritis. ( Becskei, C; Chaudhry, Y; Payne-Johnson, M; Stegemann, MR, 2015) |
| "To determine the optimal method for use of the Canine Brief Pain Inventory (CBPI) to quantitate responses of dogs with osteoarthritis to treatment with carprofen or placebo." | 9.17 | Power of treatment success definitions when the Canine Brief Pain Inventory is used to evaluate carprofen treatment for the control of pain and inflammation in dogs with osteoarthritis. ( Bell, M; Brown, DC; Rhodes, L, 2013) |
| " In this study, the efficacy and tolerability of robenacoxib were compared with those of carprofen in canine osteoarthritis in a multi-centre, prospective, randomized, blinded, positive-controlled noninferiority clinical trial." | 9.16 | Robenacoxib vs. carprofen for the treatment of canine osteoarthritis; a randomized, noninferiority clinical trial. ( Gruet, P; King, JN; Reymond, N; Seewald, W; Speranza, C, 2012) |
| "The efficacy and tolerability of robenacoxib for the treatment of osteoarthritis in dogs were evaluated in a prospective, multicenter, randomized, noninferiority design clinical trial." | 9.16 | Comparison of oral robenacoxib and carprofen for the treatment of osteoarthritis in dogs: a randomized clinical trial. ( Edamura, K; King, JN; Okumura, M; Sakakibara, N; Seewald, W, 2012) |
| "Results suggested that in dogs with chronic osteoarthritis receiving carprofen because of signs of pain, feeding a diet supplemented with fish oil omega-3 fatty acids may allow for a reduction in carprofen dosage." | 9.14 | A multicenter study of the effect of dietary supplementation with fish oil omega-3 fatty acids on carprofen dosage in dogs with osteoarthritis. ( Allen, TA; Brejda, J; Dodd, CE; Fritsch, DA; Hahn, KA; Jewell, DE; Leventhal, PS; Sixby, KA, 2010) |
| "A double-blind, randomised, controlled, multicentre field study was conducted to compare the safety and efficacy of firocoxib chewable tablets and carprofen tablets in 218 dogs with osteoarthritis." | 9.12 | Clinical evaluation of firocoxib and carprofen for the treatment of dogs with osteoarthritis. ( Fleishman, C; Hanson, PD; Pollmeier, M; Toulemonde, C, 2006) |
| "Thirty-five dogs were included in a randomised, double-blind, positive controlled, multi-centre trial to assess the efficacy of an orally-administered glucosamine hydrochloride and chondroitin sulfate (Glu/CS) combination for the treatment of confirmed osteoarthritis of hips or elbows." | 9.12 | Randomised double-blind, positive-controlled trial to assess the efficacy of glucosamine/chondroitin sulfate for the treatment of dogs with osteoarthritis. ( Jones, B; McAllister, H; McCarthy, G; Mooney, C; O'Donovan, J; Seed, M, 2007) |
| "Six medium to large breed dogs with osteoarthritis were treated with 2 mg/kg of racemic carprofen, mixed with their morning feed, daily for 28 days." | 9.10 | Clinical efficacy and pharmacokinetics of carprofen in the treatment of dogs with osteoarthritis. ( AliAbadi, FS; Lees, P; Lipscomb, VJ; Muir, P; Pead, MJ, 2002) |
| "The efficacy, tolerance and ease of administration of a nutraceutical, carprofen or meloxicam were evaluated in a prospective, double-blind study on 71 dogs with osteoarthritis." | 9.10 | Clinical evaluation of a nutraceutical, carprofen and meloxicam for the treatment of dogs with osteoarthritis. ( Bonneau, NH; Desnoyers, M; Dupuis, J; Moreau, M, 2003) |
| "The pain-relieving effect of carprofen and tolerance to the drug were investigated in 805 dogs that were lame as a result of osteoarthritis." | 7.74 | Long-term treatment with carprofen of 805 dogs with osteoarthritis. ( Grøndahl, C; Lønaas, L; Mansa, S; Nyman, G; Palmér, E, 2007) |
| "To evaluate in vivo activity of carprofen, deracoxib, and etodolac on prostanoid production in several target tissues in dogs with chronic osteoarthritis." | 7.73 | In vivo effects of carprofen, deracoxib, and etodolac on prostanoid production in blood, gastric mucosa, and synovial fluid in dogs with chronic osteoarthritis. ( Budsberg, SC; Reynolds, LR; Sessions, JK, 2005) |
| "The purpose of this study was to evaluate the effect of the administration of meloxicam; carprofen; and a slow-acting disease modifying osteoarthritis agent, that contains chondroitin sulfate, purified glucosamine, and manganese ascorbate (CS-G-M), on thyroid function in dogs." | 7.72 | Effects of oral administration of meloxicam, carprofen, and a nutraceutical on thyroid function in dogs with osteoarthritis. ( Beauchamp, G; Dupuis, J; Moreau, M; Paradis, M; Refsal, KR; Sauvé, F, 2003) |
| "To determine effects of carprofen and dexamethasone on chondrocytes in a culture model of osteoarthritis (OA)." | 7.71 | Effects of carprofen and dexamethasone on canine chondrocytes in a three-dimensional culture model of osteoarthritis. ( Cook, JL; Dvorak, LD; Kreeger, JM; Kuroki, K; Tomlinson, JL, 2002) |
| "Carprofen is a propionic acid-derived NSAID that has anti-inflammatory, analgesic, and antipyretic activity." | 6.40 | Use of carprofen for the treatment of pain and inflammation in dogs. ( Fox, SM; Johnston, SA, 1997) |
| " In explant culture, low MW HA combined with 12." | 5.42 | Effects of low molecular weight hyaluronan combined with carprofen on canine osteoarthritis articular chondrocytes and cartilage explants in vitro. ( Buddhachat, K; Chomdej, S; Euppayo, T; Harada, Y; Nganvongpanit, K; Ongchai, S; Pradit, W; Siengdee, P; Viriyakhasem, N, 2015) |
| "Carprofen treatment decreased the width of osteophytes (p < 0." | 5.31 | Carprofen simultaneously reduces progression of morphological changes in cartilage and subchondral bone in experimental dog osteoarthritis. ( Fernandes, JC; Hilal, G; Jolicoeur, FC; Jovanovic, DV; Lajeunesse, D; Lascau-Coman, V; Martel-Pelletier, J; Pelletier, JP, 2000) |
| "A multi-site, masked, randomised parallel group study employing a double dummy treatment design was performed in canine veterinary patients to determine the comparative efficacy and safety of mavacoxib and carprofen in the treatment of pain and inflammation associated with osteoarthritis for a period of 134 days." | 5.20 | Comparative efficacy and safety of mavacoxib and carprofen in the treatment of canine osteoarthritis. ( Becskei, C; Chaudhry, Y; Payne-Johnson, M; Stegemann, MR, 2015) |
| "To determine the optimal method for use of the Canine Brief Pain Inventory (CBPI) to quantitate responses of dogs with osteoarthritis to treatment with carprofen or placebo." | 5.17 | Power of treatment success definitions when the Canine Brief Pain Inventory is used to evaluate carprofen treatment for the control of pain and inflammation in dogs with osteoarthritis. ( Bell, M; Brown, DC; Rhodes, L, 2013) |
| "The efficacy and tolerability of robenacoxib for the treatment of osteoarthritis in dogs were evaluated in a prospective, multicenter, randomized, noninferiority design clinical trial." | 5.16 | Comparison of oral robenacoxib and carprofen for the treatment of osteoarthritis in dogs: a randomized clinical trial. ( Edamura, K; King, JN; Okumura, M; Sakakibara, N; Seewald, W, 2012) |
| " In this study, the efficacy and tolerability of robenacoxib were compared with those of carprofen in canine osteoarthritis in a multi-centre, prospective, randomized, blinded, positive-controlled noninferiority clinical trial." | 5.16 | Robenacoxib vs. carprofen for the treatment of canine osteoarthritis; a randomized, noninferiority clinical trial. ( Gruet, P; King, JN; Reymond, N; Seewald, W; Speranza, C, 2012) |
| " In the carprofen and placebo groups, there was poor correlation between the 2 pain evaluation methods (VAS and HCPI items) at the baseline evaluation, but the correlation improved in the carprofen group over time." | 5.15 | Reliability and validity of a visual analogue scale used by owners to measure chronic pain attributable to osteoarthritis in their dogs. ( Hielm-Björkman, AK; Kapatkin, AS; Rita, HJ, 2011) |
| "Results suggested that in dogs with chronic osteoarthritis receiving carprofen because of signs of pain, feeding a diet supplemented with fish oil omega-3 fatty acids may allow for a reduction in carprofen dosage." | 5.14 | A multicenter study of the effect of dietary supplementation with fish oil omega-3 fatty acids on carprofen dosage in dogs with osteoarthritis. ( Allen, TA; Brejda, J; Dodd, CE; Fritsch, DA; Hahn, KA; Jewell, DE; Leventhal, PS; Sixby, KA, 2010) |
| "To determine whether an activity monitor (AM) could be used to detect changes in activity in dogs with osteoarthritis treated with carprofen or a placebo." | 5.14 | Use of an activity monitor to detect response to treatment in dogs with osteoarthritis. ( Boston, RC; Brown, DC; Farrar, JT, 2010) |
| "Thirty-five dogs were included in a randomised, double-blind, positive controlled, multi-centre trial to assess the efficacy of an orally-administered glucosamine hydrochloride and chondroitin sulfate (Glu/CS) combination for the treatment of confirmed osteoarthritis of hips or elbows." | 5.12 | Randomised double-blind, positive-controlled trial to assess the efficacy of glucosamine/chondroitin sulfate for the treatment of dogs with osteoarthritis. ( Jones, B; McAllister, H; McCarthy, G; Mooney, C; O'Donovan, J; Seed, M, 2007) |
| "A double-blind, randomised, controlled, multicentre field study was conducted to compare the safety and efficacy of firocoxib chewable tablets and carprofen tablets in 218 dogs with osteoarthritis." | 5.12 | Clinical evaluation of firocoxib and carprofen for the treatment of dogs with osteoarthritis. ( Fleishman, C; Hanson, PD; Pollmeier, M; Toulemonde, C, 2006) |
| "The efficacy, tolerance and ease of administration of a nutraceutical, carprofen or meloxicam were evaluated in a prospective, double-blind study on 71 dogs with osteoarthritis." | 5.10 | Clinical evaluation of a nutraceutical, carprofen and meloxicam for the treatment of dogs with osteoarthritis. ( Bonneau, NH; Desnoyers, M; Dupuis, J; Moreau, M, 2003) |
| "Six medium to large breed dogs with osteoarthritis were treated with 2 mg/kg of racemic carprofen, mixed with their morning feed, daily for 28 days." | 5.10 | Clinical efficacy and pharmacokinetics of carprofen in the treatment of dogs with osteoarthritis. ( AliAbadi, FS; Lees, P; Lipscomb, VJ; Muir, P; Pead, MJ, 2002) |
| "The pain-relieving effect of carprofen and tolerance to the drug were investigated in 805 dogs that were lame as a result of osteoarthritis." | 3.74 | Long-term treatment with carprofen of 805 dogs with osteoarthritis. ( Grøndahl, C; Lønaas, L; Mansa, S; Nyman, G; Palmér, E, 2007) |
| "To evaluate in vivo activity of carprofen, deracoxib, and etodolac on prostanoid production in several target tissues in dogs with chronic osteoarthritis." | 3.73 | In vivo effects of carprofen, deracoxib, and etodolac on prostanoid production in blood, gastric mucosa, and synovial fluid in dogs with chronic osteoarthritis. ( Budsberg, SC; Reynolds, LR; Sessions, JK, 2005) |
| "The purpose of this study was to evaluate the effect of the administration of meloxicam; carprofen; and a slow-acting disease modifying osteoarthritis agent, that contains chondroitin sulfate, purified glucosamine, and manganese ascorbate (CS-G-M), on thyroid function in dogs." | 3.72 | Effects of oral administration of meloxicam, carprofen, and a nutraceutical on thyroid function in dogs with osteoarthritis. ( Beauchamp, G; Dupuis, J; Moreau, M; Paradis, M; Refsal, KR; Sauvé, F, 2003) |
| "To determine effects of carprofen and dexamethasone on chondrocytes in a culture model of osteoarthritis (OA)." | 3.71 | Effects of carprofen and dexamethasone on canine chondrocytes in a three-dimensional culture model of osteoarthritis. ( Cook, JL; Dvorak, LD; Kreeger, JM; Kuroki, K; Tomlinson, JL, 2002) |
| "Treatment with carprofen decreased clot strength and platelet aggregation." | 2.73 | Changes in platelet function, hemostasis, and prostaglandin expression after treatment with nonsteroidal anti-inflammatory drugs with various cyclooxygenase selectivities in dogs. ( Brainard, BM; Budsberg, SC; Callan, MB; Driessen, B; Meredith, CP; Otto, CM; Shofer, FS, 2007) |
| "To evaluate the adverse effects of carprofen in dogs after oral administration for 2 months." | 2.72 | Evaluation of adverse effects of long-term orally administered carprofen in dogs. ( Hielm-Björkman, AK; Kejonen, J; Raekallio, MR; Salonen, HM; Sankari, SM, 2006) |
| "Carprofen is a propionic acid-derived NSAID that has anti-inflammatory, analgesic, and antipyretic activity." | 2.40 | Use of carprofen for the treatment of pain and inflammation in dogs. ( Fox, SM; Johnston, SA, 1997) |
| " In explant culture, low MW HA combined with 12." | 1.42 | Effects of low molecular weight hyaluronan combined with carprofen on canine osteoarthritis articular chondrocytes and cartilage explants in vitro. ( Buddhachat, K; Chomdej, S; Euppayo, T; Harada, Y; Nganvongpanit, K; Ongchai, S; Pradit, W; Siengdee, P; Viriyakhasem, N, 2015) |
| "Suspected adverse reactions (SARs) reported for Cartrophen Vet (100 mg sodium pentosan polysulphate/ml) to the Veterinary Medicines Directorate in the UK for the period January 1991 to October 1999 were reviewed." | 1.32 | Safety of Cartrophen Vet in the dog: review of adverse reaction reports in the UK. ( Cawdery, MJ; Cullis-Hill, D; Ghosh, P; Hannon, RL; Smith, JG, 2003) |
| "Carprofen treatment decreased the width of osteophytes (p < 0." | 1.31 | Carprofen simultaneously reduces progression of morphological changes in cartilage and subchondral bone in experimental dog osteoarthritis. ( Fernandes, JC; Hilal, G; Jolicoeur, FC; Jovanovic, DV; Lajeunesse, D; Lascau-Coman, V; Martel-Pelletier, J; Pelletier, JP, 2000) |
| "Carprofen has a direct influence on chondrocyte activity, resulting in changes in rate of production of cartilage matrix." | 1.30 | Effect of carprofen on sulfated glycosaminoglycan metabolism, protein synthesis, and prostaglandin release by cultured osteoarthritic canine chondrocytes. ( Benton, HP; Broderick-Villa, GA; Koolpe, M; Vasseur, PB, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (14.63) | 18.7374 |
| 1990's | 5 (12.20) | 18.2507 |
| 2000's | 15 (36.59) | 29.6817 |
| 2010's | 14 (34.15) | 24.3611 |
| 2020's | 1 (2.44) | 2.80 |
| Authors | Studies |
|---|---|
| White, C | 1 |
| Morrow, L | 1 |
| Belshaw, Z | 1 |
| Brennan, M | 1 |
| AlRaddadi, EA | 1 |
| Winter, T | 1 |
| Aukema, HM | 1 |
| Miller, DW | 1 |
| Brown, DC | 4 |
| Bell, M | 1 |
| Rhodes, L | 1 |
| Poulet, B | 1 |
| de Souza, R | 1 |
| Knights, CB | 1 |
| Gentry, C | 1 |
| Wilson, AM | 1 |
| Bevan, S | 1 |
| Chang, YM | 1 |
| Pitsillides, AA | 1 |
| Payne-Johnson, M | 1 |
| Becskei, C | 1 |
| Chaudhry, Y | 1 |
| Stegemann, MR | 1 |
| Bruno, EA | 1 |
| Guthrie, JW | 1 |
| Ellwood, SA | 1 |
| Mellanby, RJ | 1 |
| Clements, DN | 1 |
| Euppayo, T | 1 |
| Siengdee, P | 1 |
| Buddhachat, K | 1 |
| Pradit, W | 1 |
| Viriyakhasem, N | 1 |
| Chomdej, S | 1 |
| Ongchai, S | 1 |
| Harada, Y | 1 |
| Nganvongpanit, K | 1 |
| Fernando, N | 1 |
| Wu, E | 1 |
| Kou, C | 1 |
| Martelli, P | 1 |
| Khong, LF | 1 |
| Larson, K | 1 |
| Boston, RC | 2 |
| Coyne, JC | 1 |
| Farrar, JT | 2 |
| Fritsch, DA | 1 |
| Allen, TA | 1 |
| Dodd, CE | 1 |
| Jewell, DE | 1 |
| Sixby, KA | 1 |
| Leventhal, PS | 1 |
| Brejda, J | 1 |
| Hahn, KA | 1 |
| Reymond, N | 1 |
| Speranza, C | 1 |
| Gruet, P | 1 |
| Seewald, W | 2 |
| King, JN | 2 |
| Hielm-Björkman, AK | 2 |
| Kapatkin, AS | 1 |
| Rita, HJ | 1 |
| Edamura, K | 1 |
| Sakakibara, N | 1 |
| Okumura, M | 1 |
| Dvorak, LD | 1 |
| Cook, JL | 1 |
| Kreeger, JM | 1 |
| Kuroki, K | 1 |
| Tomlinson, JL | 1 |
| Moreau, M | 2 |
| Dupuis, J | 2 |
| Bonneau, NH | 1 |
| Desnoyers, M | 1 |
| Hannon, RL | 1 |
| Smith, JG | 1 |
| Cullis-Hill, D | 1 |
| Ghosh, P | 1 |
| Cawdery, MJ | 1 |
| Sauvé, F | 1 |
| Paradis, M | 1 |
| Refsal, KR | 1 |
| Beauchamp, G | 1 |
| Sessions, JK | 1 |
| Reynolds, LR | 1 |
| Budsberg, SC | 4 |
| Raekallio, MR | 1 |
| Kejonen, J | 1 |
| Salonen, HM | 1 |
| Sankari, SM | 1 |
| McCarthy, G | 1 |
| O'Donovan, J | 1 |
| Jones, B | 1 |
| McAllister, H | 1 |
| Seed, M | 1 |
| Mooney, C | 1 |
| Pollmeier, M | 1 |
| Toulemonde, C | 1 |
| Fleishman, C | 1 |
| Hanson, PD | 1 |
| Brainard, BM | 1 |
| Meredith, CP | 1 |
| Callan, MB | 1 |
| Shofer, FS | 1 |
| Driessen, B | 1 |
| Otto, CM | 1 |
| Mansa, S | 1 |
| Palmér, E | 1 |
| Grøndahl, C | 1 |
| Lønaas, L | 1 |
| Nyman, G | 1 |
| Liesegang, A | 1 |
| Limacher, S | 1 |
| Sobek, A | 1 |
| Pipino, F | 1 |
| Busetto, M | 1 |
| Franchin, F | 1 |
| Punzi, L | 1 |
| Todesco, S | 1 |
| Cozzolino, F | 1 |
| Costa, L | 1 |
| Marasco, E | 1 |
| Kaufmann, S | 1 |
| Schlumpf, U | 1 |
| Klein, B | 1 |
| Knüsel, O | 1 |
| Vasseur, PB | 2 |
| Johnson, AL | 1 |
| Lincoln, JD | 1 |
| Toombs, JP | 1 |
| Whitehair, JG | 1 |
| Lentz, EL | 1 |
| Benton, HP | 1 |
| Broderick-Villa, GA | 1 |
| Koolpe, M | 1 |
| Fox, SM | 1 |
| Johnston, SA | 1 |
| Armstrong, S | 1 |
| Lees, P | 2 |
| Pelletier, JP | 2 |
| Lajeunesse, D | 2 |
| Hilal, G | 2 |
| Jovanovic, D | 1 |
| Fernandes, JC | 2 |
| Martel-Pelletier, J | 2 |
| Jovanovic, DV | 1 |
| Lascau-Coman, V | 1 |
| Jolicoeur, FC | 1 |
| Lipscomb, VJ | 1 |
| AliAbadi, FS | 1 |
| Pead, MJ | 1 |
| Muir, P | 1 |
3 reviews available for carprofen and Osteoarthritis
| Article | Year |
|---|---|
Efficacy of meloxicam compared with carprofen for treating canine osteoarthritis.
Topics: Animals; Carbazoles; Dog Diseases; Dogs; Meloxicam; Osteoarthritis; Randomized Controlled Trials as | 2020 |
[The introduction of non-steroidal antirheumatics: is there a rational therapy].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Carbazoles; Chronic Disease; Diclofe | 1982 |
Use of carprofen for the treatment of pain and inflammation in dogs.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; | 1997 |
20 trials available for carprofen and Osteoarthritis
| Article | Year |
|---|---|
Power of treatment success definitions when the Canine Brief Pain Inventory is used to evaluate carprofen treatment for the control of pain and inflammation in dogs with osteoarthritis.
Topics: Analysis of Variance; Animals; Anti-Inflammatory Agents, Non-Steroidal; Carbazoles; Dog Diseases; Do | 2013 |
The Canine Orthopedic Index. Step 3: Responsiveness testing.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Carbazoles; Cohort Studies; Data Collection; Dog D | 2014 |
Comparative efficacy and safety of mavacoxib and carprofen in the treatment of canine osteoarthritis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Carbazoles; Dog Diseases; Dogs; Double-Blind Metho | 2015 |
Ability of the canine brief pain inventory to detect response to treatment in dogs with osteoarthritis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Carbazoles; Dog Diseases; Dogs; Double-Blind Metho | 2008 |
A multicenter study of the effect of dietary supplementation with fish oil omega-3 fatty acids on carprofen dosage in dogs with osteoarthritis.
Topics: Animals; Carbazoles; Dietary Supplements; Dog Diseases; Dogs; Dose-Response Relationship, Drug; Drug | 2010 |
Use of an activity monitor to detect response to treatment in dogs with osteoarthritis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Carbazoles; Dog Diseases; Dogs; Female; Male; Moni | 2010 |
Robenacoxib vs. carprofen for the treatment of canine osteoarthritis; a randomized, noninferiority clinical trial.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Carbazoles; Diphenylamine; Dog Diseases; Dogs; Fem | 2012 |
Reliability and validity of a visual analogue scale used by owners to measure chronic pain attributable to osteoarthritis in their dogs.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Carbazoles; Chronic Disease; Dog Diseases; Dogs; F | 2011 |
Comparison of oral robenacoxib and carprofen for the treatment of osteoarthritis in dogs: a randomized clinical trial.
Topics: Administration, Oral; Analysis of Variance; Animals; Carbazoles; Diphenylamine; Dog Diseases; Dogs; | 2012 |
Clinical evaluation of a nutraceutical, carprofen and meloxicam for the treatment of dogs with osteoarthritis.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Ascorbic Acid; Carbazoles; C | 2003 |
Evaluation of adverse effects of long-term orally administered carprofen in dogs.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Blood Proteins; Carbazoles; | 2006 |
Randomised double-blind, positive-controlled trial to assess the efficacy of glucosamine/chondroitin sulfate for the treatment of dogs with osteoarthritis.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Carbazoles; Chondroitin Sulf | 2007 |
Clinical evaluation of firocoxib and carprofen for the treatment of dogs with osteoarthritis.
Topics: 4-Butyrolactone; Animals; Anti-Inflammatory Agents, Non-Steroidal; Carbazoles; Dog Diseases; Dogs; D | 2006 |
Changes in platelet function, hemostasis, and prostaglandin expression after treatment with nonsteroidal anti-inflammatory drugs with various cyclooxygenase selectivities in dogs.
Topics: Animals; Aspirin; Carbazoles; Cross-Over Studies; Cyclooxygenase Inhibitors; Dog Diseases; Dogs; Fem | 2007 |
[Treatment of osteoarthrosis with a new nonsteroidal anti-inflammatory agent, carprofen].
Topics: Adult; Aged; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Carbazoles; Clinical | 1984 |
[The clinical efficacy and tolerance of a new anti-inflammatory agent, carprofen, in osteoarthritis. Comparative double-blind study with naproxen].
Topics: Adult; Aged; Anti-Inflammatory Agents; Carbazoles; Clinical Trials as Topic; Double-Blind Method; Dr | 1983 |
Carprofen in osteoarthrosis.
Topics: Adult; Anti-Inflammatory Agents; Carbazoles; Clinical Trials as Topic; Double-Blind Method; Drug Adm | 1982 |
Double-blind comparative clinical trial of carprofen versus diclofenac-Na in patients with coxarthrosis.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Carbazoles; Clinical Trials as Topic; Diclofen | 1982 |
Randomized, controlled trial of the efficacy of carprofen, a nonsteroidal anti-inflammatory drug, in the treatment of osteoarthritis in dogs.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Carbazoles; Dog Diseases; Dogs; Female; Male; Oste | 1995 |
Clinical efficacy and pharmacokinetics of carprofen in the treatment of dogs with osteoarthritis.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Area Under Curve; Breeding; | 2002 |
18 other studies available for carprofen and Osteoarthritis
| Article | Year |
|---|---|
Are nutraceuticals better than carprofen at controlling osteoarthritis in dogs?
Topics: Animals; Carbazoles; Clinical Decision-Making; Controlled Clinical Trials as Topic; Dietary Suppleme | 2018 |
Effects of various dietary supplements on inflammatory processes in primary canine chondrocytes as a model of osteoarthritis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Carbazoles; Cell Survival; Cells, Cultured; Chondr | 2019 |
Modifications of gait as predictors of natural osteoarthritis progression in STR/Ort mice.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthralgia; Carbazoles; Disease Models, Animal; Di | 2014 |
Global positioning system derived performance measures are responsive indicators of physical activity, disease and the success of clinical treatments in domestic dogs.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Carbazoles; Dog Diseases; Dogs; Female; Geographic | 2015 |
Effects of low molecular weight hyaluronan combined with carprofen on canine osteoarthritis articular chondrocytes and cartilage explants in vitro.
Topics: Adjuvants, Immunologic; Animals; Anti-Inflammatory Agents, Non-Steroidal; Carbazoles; Cartilage, Art | 2015 |
MANAGEMENT OF OSTEOARTHRITIS IN A GIANT PANDA (AILUROPODA MELANOLEUCA) WITH MULTIMODAL THERAPY INCLUDING AMANTADINE SULPHATE.
Topics: Amantadine; Analgesics, Non-Narcotic; Animals; Animals, Zoo; Anti-Inflammatory Agents, Non-Steroidal | 2016 |
Effects of carprofen and dexamethasone on canine chondrocytes in a three-dimensional culture model of osteoarthritis.
Topics: Animals; Carbazoles; Cartilage, Articular; Cells, Cultured; Chondrocytes; Collagenases; Dexamethason | 2002 |
Safety of Cartrophen Vet in the dog: review of adverse reaction reports in the UK.
Topics: Adverse Drug Reaction Reporting Systems; Animals; Anti-Inflammatory Agents, Non-Steroidal; Breeding; | 2003 |
Effects of oral administration of meloxicam, carprofen, and a nutraceutical on thyroid function in dogs with osteoarthritis.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Autoantibodies; Carbazoles; | 2003 |
In vivo effects of carprofen, deracoxib, and etodolac on prostanoid production in blood, gastric mucosa, and synovial fluid in dogs with chronic osteoarthritis.
Topics: Animals; Carbazoles; Cyclooxygenase Inhibitors; Dinoprostone; Dog Diseases; Dogs; Drug Administratio | 2005 |
Long-term treatment with carprofen of 805 dogs with osteoarthritis.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Carbazoles; Dog Diseases; Do | 2007 |
The effect of carprofen on selected markers of bone metabolism in dogs with chronic osteoarthritis.
Topics: Age Factors; Analysis of Variance; Animals; Anti-Inflammatory Agents, Non-Steroidal; Biomarkers; Bon | 2007 |
[Clinical experiences with the antirheumatism agent carprofen].
Topics: Arthritis, Rheumatoid; Carbazoles; Female; Humans; Male; Middle Aged; Osteoarthritis; Spondylitis, A | 1983 |
Effect of carprofen on sulfated glycosaminoglycan metabolism, protein synthesis, and prostaglandin release by cultured osteoarthritic canine chondrocytes.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Carbazoles; Cartilage, Articular; Cell Division; C | 1997 |
Effects of R and S enantiomers and a racemic mixture of carprofen on the production and release of proteoglycan and prostaglandin E2 from equine chondrocytes and cartilage explants.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Carbazoles; Cartilage, Articular; Cells, Cultured; | 1999 |
Carprofen reduces the structural changes and the abnormal subchondral bone metabolism of experimental osteoarthritis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Bone and Bones; Bone Remodeling; Carbazoles; Carti | 1999 |
Carprofen simultaneously reduces progression of morphological changes in cartilage and subchondral bone in experimental dog osteoarthritis.
Topics: Alkaline Phosphatase; Animals; Anti-Inflammatory Agents, Non-Steroidal; Bone and Bones; Carbazoles; | 2000 |
Long-term temporal evaluation of ground reaction forces during development of experimentally induced osteoarthritis in dogs.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Biomechanical Phenomena; Carbazoles; Dog Diseases; | 2001 |